Elicera Therapeutics AB (publ) Year-End Report 1 January – 31 December 2023
Fourth quarter (October-December 2023) · Operating profit/loss amounted to SEK -5,212,694 (-3,951,799). · Loss for the period amounted to SEK -4,749,222 (-3,898,340). · Cash flow from operating activities totaled SEK 3,503,148 (5,516,307). · Earnings per share before dilution totaled SEK -0.24 (-0.20). Earnings per share after dilution totaled SEK -0.24 (-0.20). · Proposed dividend of SEK 0.00 per share (0.00 for the preceding year). Period (January-December 2023) · Operating profit/loss amounted to SEK -17,096,277 (-19,362,750). · Loss for the period